Prostate cancer detection in men with a 'normal' total prostate-specific antigen (PSA) level using percentage free PSA: a prospective screening study
作者： Edward W.J. Rowe , Mark E. Laniado , Marjorie M. Walker , Anup Patel
DOI: 10.1111/J.1464-410X.2005.05514.X
关键词:
摘要: OBJECTIVE To assess the utility of percentage free/total prostate-specific antigen (f/tPSA) levels for detecting prostate cancer in a prospectively screened population men with ‘normal’ total PSA level. PATIENTS AND METHODS Men aged 50–65 years were contacted via their general practitioner and invited screening. All had f/tPSA measured; those meeting biopsy criteria (PSA 1.1–3.99 ng/mL ≤ 20%) offered biopsy. The detection rate was then evaluated compared other methods detection. In all, 773 screened, whom 115 met agreed to undergo biopsy. RESULTS Cancer detected 13 (11.3%) most would have been missed by lowering age-adjusted threshold 2.5 ng/mL. There no significant difference values without cancer. Those cancers that could be found clinically significant. CONCLUSION In this study solely on basis low value. Most simply PSA. Using level may allow at time when they are likely benefit from treatment.
sci-hub.se 参考文章(14)
William J Catalona, Alan W Partin, Judith A Finlay, Daniel W Chan, Harry G Rittenhouse, Robert L Wolfert, David L Woodrum, Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology. ,vol. 54, pp. 220- 224 ,(1999) , 10.1016/S0090-4295(99)00185-5
Olli S Miettinen, Claudia I Henschke, Mark W Pasmantier, James P Smith, Daniel M Libby, David F Yankelevitz, Mammographic screening: no reliable supporting evidence? The Lancet. ,vol. 359, pp. 404- 405 ,(2002) , 10.1016/S0140-6736(02)07592-X
William J. Catalona, Prostate Cancer Detection in Men With Serum PSA Concentrations of 2.6 to 4.0 ng/mL and Benign Prostate Examination JAMA. ,vol. 277, pp. 1452- 1455 ,(1997) , 10.1001/JAMA.1997.03540420048028
Jonathan I. Epstein, Pathologic and Clinical Findings to Predict Tumor Extent of Nonpalpable (Stage T1 c) Prostate Cancer JAMA: The Journal of the American Medical Association. ,vol. 271, pp. 368- 374 ,(1994) , 10.1001/JAMA.1994.03510290050036
FRITZ H. SCHRÖDER, INGRID van der CRUIJSEN-KOETER, HARRY J. de KONING, ANDRÉ N. VIS, ROBERT F. HOEDEMAEKER, RIES KRANSE, Prostate cancer detection at low prostate specific antigen. The Journal of Urology. ,vol. 163, pp. 806- 812 ,(2000) , 10.1016/S0022-5347(05)67809-3
Alan W. Partin, Combination of Prostate-Specific Antigen, Clinical Stage, and Gleason Score to Predict Pathological Stage of Localized Prostate Cancer JAMA. ,vol. 277, pp. 1445- 1451 ,(1997) , 10.1001/JAMA.1997.03540420041027
FRANZ RECKER, MACIEJ K. KWIATKOWSKI, ANDREAS HUBER, BERNHARD STAMM, KURT LEHMANN, RETO TSCHOLL, PROSPECTIVE DETECTION OF CLINICALLY RELEVANT PROSTATE CANCER IN THE PROSTATE SPECIFIC ANTIGEN RANGE 1 TO 3 NG./ML. COMBINED WITH FREE-TO-TOTAL RATIO 20% OR LESS: THE AARAU EXPERIENCE The Journal of Urology. ,vol. 166, pp. 851- 855 ,(2001) , 10.1016/S0022-5347(05)65850-8
H Ballentine Carter, Jonathan I Epstein, Daniel W Chan, James L Fozard, Jay D Pearson, Recommended Prostate-Specific Antigen Testing Intervals for the Detection of Curable Prostate Cancer JAMA: The Journal of the American Medical Association. ,vol. 277, pp. 1456- 1460 ,(1997) , 10.1001/JAMA.1997.03540420052029
LUNG WAI CHAN, THOMAS A. STAMEY, CALCULATING PROSTATE CANCER VOLUME PREOPERATIVELY: THE D'AMICO Equation ANDSOME OTHER OBSERVATIONS The Journal of Urology. ,vol. 159, pp. 1998- 2003 ,(1998) , 10.1016/S0022-5347(01)63225-7
Janet L. Stanford, Ziding Feng, Ann S. Hamilton, Frank D. Gilliland, Robert A. Stephenson, J. William Eley, Peter C. Albertsen, Linda C. Harlan, Arnold L. Potosky, Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer : The Prostate Cancer Outcomes Study JAMA. ,vol. 283, pp. 354- 360 ,(2000) , 10.1001/JAMA.283.3.354